Black Hawk Acquisition Corporation income statement BKHAU

Net income was $1.1 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Aug 31, 2026
Q3 FY2026
Aug 31, 2026
Q2 FY2026
May 31, 2026
Q1 FY2026
Feb 28, 2026
Q4 FY2025
Nov 30, 2025
Q3 FY2025
Aug 31, 2025
Q2 FY2025
May 31, 2025
Q1 FY2025
Feb 28, 2025
Q4 FY2024
Nov 30, 2024
Selling, general and administrative
0
-41.2%
0
-65.2%
0
-63.6%
0
-69.3%
0
+163.6%
0
+466.9%
0
-35.1%
0
+156.6%
0
Operating income
-1
+35.0%
-0
+59.5%
-0
+55.9%
-0
+50.2%
-0
-115.1%
-0
-301.9%
-0
+31.1%
-0
-0
Net income
1
-37.7%
1
+596.1%
0
-82.9%
0
-78.8%
-0
-100.5%
0
-82.5%
1
+67.4%
1
+2244.5%
1
Other measures
Interest coverage
—
-4.16x
-4.48x
-2.79x
—
—
—
—
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BKHA (Nasdaq), BKHAR (Nasdaq), BKHAU (Nasdaq)
Fiscal year ends
November 30
Headquarters
Danville, CA
SEC filer status
, Emerging growth company
SEC CIK
2000775

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.